Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity

Overview of attention for article published in Regulatory Peptides, August 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 13 X posts from 13 X users, with an upper bound of 179,854 followers.

RT @DanielJDrucker: Will PYY-based medicines, in conjunction with GLP-1RA add value in the clinic #obesity #T2D https://t.co/nTHLqic9QL htt…

RT @DanielJDrucker: Will PYY-based medicines, in conjunction with GLP-1RA add value in the clinic #obesity #T2D https://t.co/nTHLqic9QL htt…

RT @DanielJDrucker: Will PYY-based medicines, in conjunction with GLP-1RA add value in the clinic #obesity #T2D https://t.co/nTHLqic9QL htt…

RT @DanielJDrucker: Will PYY-based medicines, in conjunction with GLP-1RA add value in the clinic #obesity #T2D https://t.co/nTHLqic9QL htt…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 9 additional X posts.